Home › Research › Biomarkers
Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer's disease using a proteomics approach
Siti Hajar Rehiman, Siong Meng Lim, Fei Tieng Lim, Ai-Vyrn Chin, Maw Pin Tan, Shahrul Bahyah Kamaruzzaman, Kalavathy Ramasamy, Abu Bakar Abdul Majeed. The International journal of neuroscience, 2020-12-15
Topic: Plasma and spinal-fluid biomarkers
Mass spectrometry (MS)-based protein identification via MALDI ToF/ToF showed that fibrinogen-β-chain (spot 64) and fibrinogen-γ-chain (spot 91) with differential expression ratio >1.5 were significantly upregulated (p < 0.05) in AD patients when compared to non-AD individuals. Further data analysis using Pearson correlation found that the upregulated fibrinogen-γ-chain was weakly but significantly (p < 0.05) and inversely correlated with cognitive decline. Fibrinogen isoforms may play important roles in the vascular pathology of AD as well as neuroinflammation. As such, fibrinogen appears to be a promising blood-based biomarker for AD. Further validation of the present findings in larger population is now warranted.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rehiman, S. H., Lim, S. M., Lim, F. T., Chin, A.-V., Tan, M. P., Kamaruzzaman, S. B., et al. (2022). Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer's disease using a proteomics approach. The International journal of neuroscience. https://doi.org/10.1080/00207454.2020.1860038
Vancouver
Rehiman SH, Lim SM, Lim FT, Chin A.-V, Tan MP, Kamaruzzaman SB, et al. Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer's disease using a proteomics approach. The International journal of neuroscience. 2022. doi:10.1080/00207454.2020.1860038. PMID: 33280461.
BibTeX
@article{rehiman2022-33280461,
author = {Rehiman, Siti Hajar and Lim, Siong Meng and Lim, Fei Tieng and Chin, Ai-Vyrn and Tan, Maw Pin and Kamaruzzaman, Shahrul Bahyah and Ramasamy, Kalavathy and Majeed, Abu Bakar Abdul},
title = {{Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer's disease using a proteomics approach}},
journal = {The International journal of neuroscience},
year = {2022},
doi = {10.1080/00207454.2020.1860038},
pmid = {33280461},
url = {https://doi.org/10.1080/00207454.2020.1860038}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Mass spectrometry (MS)-based protein identification via MALDI ToF/ToF showed that fibrinogen-β-chain (spot 64) and fibrinogen-γ-chain (spot 91) with differential expression ratio >1.5 were significantly upregulated (p < 0.05) in AD patients when compared to non-AD individuals.
- Further data analysis using Pearson correlation found that the upregulated fibrinogen-γ-chain was weakly but significantly (p < 0.05) and inversely correlated with cognitive decline.
- Fibrinogen isoforms may play important roles in the vascular pathology of AD as well as neuroinflammation.
- As such, fibrinogen appears to be a promising blood-based biomarker for AD.
- Further validation of the present findings in larger population is now warranted.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The International journal of neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33280461) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.